Previous close | 0.0500 |
Open | 0.0500 |
Bid | 0.0500 |
Ask | 0.5000 |
Strike | 1.00 |
Expiry date | 2024-09-20 |
Day's range | 0.0500 - 0.0500 |
Contract range | N/A |
Volume | |
Open interest | 168 |
SALT LAKE CITY, May 14, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis and multiple sclerosis, today announced that it will participate in the following investor conferences in May. Mizuho Neuroscienc
Clene ( NASDAQ:CLNN ) First Quarter 2024 Results Key Financial Results Net loss: US$11.1m (loss narrowed by 5.9% from...
Data from long-term extension of Phase 2 VISIONARY-MS clinical trial of CNM-Au8® demonstrated significant evidence of repair and remyelination across multiple paraclinical endpoints (change from original baseline, p<0.05)Peer-reviewed publication characterized the protein corona of CNM-Au8Company received sub-award of $7.3 million from NIH grant for ALS Expanded Access ProgramCash, cash equivalents and marketable securities of $27.9 million as of March 31, 2024 SALT LAKE CITY, May 08, 2024 (GLOB